Article

Study confirms higher dose of Faslodex needed

Author(s):

In the area of hormonal therapy yesterday, there was a trial for metastatic breast cancer patients who were receiving Faslodex. This drug has been shown to delay progression and is now a standard of care. Unfortunately, we haven't really nailed down the optimal dose yet.When it was first approved, it was approved at 250 mg due to the early trials of the drug, but it quickly became apparent shortly thereafter that 500 mg seems to give you the levels you might want to inhibit breast cancer growth. Several years ago, a trial was launched comparing the two dosages. That trial, which was presented a couple of years ago, did establish 500 mg as the proper dose. At this year's SABCS, updated results showed that the higher dose improves survival. There is an improvement in the mortality rate even after patients progress and go on to other drugs. Most oncologists are using the higher dose now, but this study provides us a greater justification to use 500 mg. Fittingly, the trial is called CONFIRM.

Related Videos
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
1 expert is featured in this series.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content